Recombinant human erythropoietin to target cognitive dysfunction in bipolar 
disorder: a double-blind, randomized, placebo-controlled phase 2 trial

Miskowiak, Kamilla W.; Ehrenreich, Hannelore; Christensen, E. M.; Kessing, L. V.; Vinberg, M.

doi:10.4088/JCP.13m08839

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial

MPS-Authors

/persons/resource/persons182138

Ehrenreich, Hannelore
Clinical neuroscience, Max Planck Institute of Experimental Medicine, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Miskowiak, K. W., Ehrenreich, H., Christensen, E. M., Kessing, L. V., & Vinberg, M. (2014). Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. Journal of Clinical Psychiatry, 75(12), 1347-1355. doi:10.4088/JCP.13m08839.

Cite as: https://hdl.handle.net/11858/00-001M-0000-002A-F715-7

Abstract

There is no abstract available